p53-Bad* in a Hepatocellular Carcinoma Mouse Model
Bowman, K. E. R.; Lu, P.; Lim, C. S.
Show abstract
Recent advances in liver cancer treatments have not changed the fact that the majority of patients will not survive the disease. In order to advance future liver cancer treatments, this work presents an exploration of various iterations of the liver cancer specific AFP promoter as well as the gene construct p53-Bad*. p53-Bad* is a mitochondrially targeted re-engineered p53 therapy that has shown previous success in a zebrafish HCC model. Both the most promising AFP promoter and p53-Bad* were packaged in an adenoviral delivery system and tested in vitro in liver cancer cell lines. Finally, mixed results for adenoviral p53-Bad* in vivo are presented, and this work suggests future modifications to study parameters in order to further explore the potential of p53-Bad* as a potential liver cancer therapeutic.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reshaping the Landscape of Locoregional Treatments for Breast Cancer Liver Metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver. 92%
- Functional analysis of promoters for driving long RNA transcripts in CAR T cells 92%
- APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression 92%
Similar papers in this journal
- RNA splicing variants of the novel long non-coding RNA, CyKILR, possess divergent biological functions in non-small cell lung cancer 92%
- Base editing strategy allows insertion of the A673T mutation in APP gene to prevent the development of Alzheimer's disease 92%
- Multiplex Gene Editing Suppresses Random Integration of Hepatitis B Virus DNA in Chronically Infected Liver 92%
Similar papers in this journal
- Hypoxia-directed tumor targeting of CRISPR/Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles 92%
- Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer 92%
- Human-specific GAPDH RT-qPCR is an accurate and sensitive method of xenograft metastasis quantification 91%
Similar papers in this journal
- Activation of PKR by a short-hairpin RNA 92%
- Analysing the effect of full-length and C-terminally truncated progranulin on proliferation, colony formation, and migration in HepG2 and U87 cells 92%
- Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory response. 92%
Similar papers in this journal
- The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity 93%
- Analysis of hepatic lentiviral vector transduction; implications for preclinical studies and clinical gene therapy protocols. 93%
- Development of SARS-CoV-2 replicons for the ancestral virus and variant of concern Delta for antiviral screening. 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.